Transthyretin Stabilizers Market size was over USD 14.16 billion in 2024 and is projected to reach USD 42.9 billion by 2037, growing at around 8.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of transthyretin stabilizers is assessed at USD 15.23 billion.
The market is witnessing a robust surge, driven primarily by the escalating prevalence of transthyretin amyloidosis (ATTR). ATTR, a rare and debilitating disease, is characterized by the abnormal accumulation of transthyretin protein, leading to organ dysfunction and a myriad of clinical manifestations.
As the incidence of ATTR rises globally, the demand for effective therapeutic interventions, including transthyretin stabilizers, is experiencing unprecedented growth. According to a recent epidemiological study, the global prevalence of ATTR has exhibited a significant increase over the past decade. In 2010, the estimated prevalence of ATTR was 10 cases per 100,000 populations, and by 2020, this figure had surged to 25 cases per 100,000 populations. This compelling statistic underscores the urgent need for therapeutic interventions, driving significant growth in the market.
Transthyretin stabilizers are drugs designed to stabilize the transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils. By stabilizing the protein, these drugs aim to slow down or halt the progression of ATTR and alleviate associated symptoms. Several transthyretin stabilizers were under development by various pharmaceutical companies. Among them, tafamidis was one of the first drugs to receive regulatory approval for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in some regions.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.9% |
|
Base Year Market Size (2024) |
USD 14.16 billion |
|
Forecast Year Market Size (2037) |
USD 42.9 billion |
|
Regional Scope |
|
Type (Tafamidis, Inotersen)
In transthyretin stabilizers market, inotersen segment is likely to dominate over 61% share by 2037. Ongoing efforts to expand inotersen's label to encompass a broader patient population contribute to its segmental growth. Label expansions based on clinical trial results provide an avenue for reaching a larger pool of ATTR patients. The successful expansion of inotersen's label to include specific genotypes previously excluded was supported by a Phase 3 study, resulting in a 25% increase in eligible patients for inotersen therapy.
Expanding patient access through label expansions not only broadens the market reach of inotersen but also addresses the unmet needs of a more diverse patient population, fostering sustained growth in its segment. Inotersen's growth in the market is further propelled by its demonstrated efficacy in polyneuropathy and cardiomyopathy management, the convenience of subcutaneous administration, and strategic efforts to expand patient access through label expansions.
End User (Hospitals, Clinics, Home Healthcare)
The hospital segment is expected to garner a significant share by the year 2037. Hospitals often serve as hubs for clinical research and trials, fostering innovation and advancing the understanding of transthyretin amyloidosis. The integration of research activities within hospital settings contributes to the development of new therapeutic interventions.
The assimilation of research and participation in clinical trials within hospitals not only positions them as centers of medical advancement but also attracts patients seeking access to cutting-edge treatments, contributing to the growth of the hospital segment. The growth of the hospital segment in the transthyretin stabilizers market is further driven by a multidisciplinary approach, access to advanced diagnostic technologies, comprehensive patient monitoring, care coordination, and the integration of research and clinical trials.
Our in-depth analysis of the global market includes the following segments:
|
Type |
|
|
End User |
|
APAC Market Forecast
Asia Pacific industry is set to dominate majority revenue share of 40% by 2037. The adoption of telehealth and remote patient monitoring solutions is contributing to the growth of the market in the Asia-Pacific region. These technological advancements improve patient access to healthcare and facilitate the remote management of transthyretin amyloidosis. Telehealth adoption in the Asia Pacific region increased by 40% in the last two years, with a notable rise in remote consultations for rare disease management.
The integration of telehealth technologies enhances patient engagement and provides a platform for effective monitoring and management of transthyretin amyloidosis, thereby supporting the growth of the market. The market in the Asia-Pacific region is further propelled by increasing disease awareness, strategic collaborations, government support, the aging population, and the adoption of innovative healthcare technologies.
North American Market Statistics
The transthyretin stabilizers market in the North American region is projected to hold the second-largest share during the forecast period. The North American region's commitment to research and development initiatives significantly propels the market. Robust investments in scientific endeavors, including clinical trials, contribute to the advancement of innovative therapies.
The North American region's commitment to research and development initiatives significantly propels the market. Robust investments in scientific endeavors, including clinical trials, contribute to the advancement of innovative therapies. The extensive research and development ecosystem in North America not only fosters the discovery of new transthyretin stabilizers but also positions the region as a key contributor to global therapeutic innovation. The escalating prevalence of transthyretin amyloidosis in North America is a fundamental driver for the transthyretin stabilizers market. A growing understanding of the disease's spectrum and improved diagnostic capabilities contribute to a higher number of identified cases.
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?